# Urology: Pelvic Sling Material Supply Phitips-Sumika: Marlex HGX-030-01 (PP)



# **History**

## <u>2005 – Initial Identification of Supply Interruption</u>

- •Phillips Summika terminates BSC contract for Marlex HGX-030-01, for use in permanent implant device.
- Contract allows last-time buy of 40K lbs.; BSC purchased 4K (10-yr supply)
- •BSC Product Affected: Urology Pelvic Sling
- •Revenue @ Risk: \$100M Annually

### 2006-2010 - Production/PD Activity

- •Initial discussions with new supplier (Borealis) positive
- •Increase in forecast and NPD consumes resin at faster rate than planned
- Stock-out date moves in from 2015 to mid-2013
- •In late 2010, Borealis reconsiders and will not sell to BSC for use in permanent implant.

# **Accomplishments**

- •Global Sourcing negotiated with distributor in China to hold additional 30K lbs. until BSC completed initial testing,
- •Equivalency testing completed in November; Biocompatibility due February 2012. Team is 90% confidant material will be approved.
- •Profax (LyondellBasell) has been identified as alternate. Based on Marlex test results, PIB will revisit need to validate an alternate. Currenlty on HOLD.

#### **Expect to mitigate potential BO completely**

(34K lbs. = 25 + yr. supply)

•Stand-alone BSC Indemnification/Insurance Agreement developed specifically addressing resin manufacturer's concern for use in implants. Additional tool for future negotiations.

## **Actions**

- •Early 2011, Phillips Summika confirms product line discontinued in 2008 timeframe; and declines request for special BSC run due to issue's with reactor. They eventually close domestic PP plant entirely at year-end.
- •Global Sourcing locates potential Marlex sources in China; makes on-site visits; confers with R&D and makes initial 4K purchase of material to test.
- •In parallel, R&D continues search for alternate material; works closely with Luxilon, the original fiber manufacturer.
- •Team from Global Sourcing and Legal initiate discussions on how to mitigate supplier concerns regarding use in implantable devices.

# Lesson's Learned

- •Increased vigilance required in monitoring consumption of lasttime buy volumes. This includes the cessation of NPD with identified material - PD/Division/Site Procurement
- •Earlier validation of alternate materials required, even when strategic buys are made PD
- •The need to continue engagement directly with resin manufacturer's to build relationships and mitigate supply issue's has become increasingly important, and has been built into Resin Commodity Strategy – Global Sourcing

Boston Scientific Confidential -- For Internal Use Only. Do Not Copy, Display or Distribute External

12